A Melanoma-Tailored Next-Generation Sequencing Panel Coupled with a Comprehensive Analysis to Improve Routine Melanoma Genotyping.
Journal
Targeted oncology
ISSN: 1776-260X
Titre abrégé: Target Oncol
Pays: France
ID NLM: 101270595
Informations de publication
Date de publication:
12 2020
12 2020
Historique:
pubmed:
6
11
2020
medline:
14
10
2021
entrez:
5
11
2020
Statut:
ppublish
Résumé
Tumor molecular deciphering is crucial in clinical management. Pan-cancer next-generation sequencing panels have moved towards exhaustive molecular characterization. However, because of treatment resistance and the growing emergence of pharmacological targets, tumor-specific customized panels are needed to guide therapeutic strategies. The objective of this study was to present such a customized next-generation sequencing panel in melanoma. Melanoma patients with somatic molecular profiling performed as part of routine care were included. High-throughput sequencing was performed with a melanoma tailored next-generation sequencing panel of 64 genes involved in molecular classification, prognosis, theranostic, and therapeutic resistance. Single nucleotide variants and copy number variations were screened, and a comprehensive molecular analysis identified clinically relevant alterations. Four hundred and twenty-one melanoma cases were analyzed (before any treatment initiation for 94.8% of patients). After bioinformatic prioritization, we uncovered 561 single nucleotide variants, 164 copy number variations, and four splice-site mutations. At least one alteration was detected in 368 (87.4%) lesions, with BRAF, NRAS, CDKN2A, CCND1, and MET as the most frequently altered genes. Among patients with BRAFV600 mutated melanoma, 44.5% (77 of 173) harbored at least one concurrent alteration driving potential resistance to mitogen-activated protein kinase inhibitors. In patients with RAS hotspot mutated lesions and in patients with neither BRAFV600 nor RAS hotspot mutations, alterations constituting potential pharmacological targets were found in 56.9% (66 of 116) and 47.7% (63 of 132) of cases, respectively. Our tailored next-generation sequencing assay coupled with a comprehensive analysis may improve therapeutic management in a significant number of patients with melanoma. Updating such a panel and implementing multi-omic approaches will further enhance patients' clinical management.
Sections du résumé
BACKGROUND
Tumor molecular deciphering is crucial in clinical management. Pan-cancer next-generation sequencing panels have moved towards exhaustive molecular characterization. However, because of treatment resistance and the growing emergence of pharmacological targets, tumor-specific customized panels are needed to guide therapeutic strategies.
OBJECTIVE
The objective of this study was to present such a customized next-generation sequencing panel in melanoma.
METHODS
Melanoma patients with somatic molecular profiling performed as part of routine care were included. High-throughput sequencing was performed with a melanoma tailored next-generation sequencing panel of 64 genes involved in molecular classification, prognosis, theranostic, and therapeutic resistance. Single nucleotide variants and copy number variations were screened, and a comprehensive molecular analysis identified clinically relevant alterations.
RESULTS
Four hundred and twenty-one melanoma cases were analyzed (before any treatment initiation for 94.8% of patients). After bioinformatic prioritization, we uncovered 561 single nucleotide variants, 164 copy number variations, and four splice-site mutations. At least one alteration was detected in 368 (87.4%) lesions, with BRAF, NRAS, CDKN2A, CCND1, and MET as the most frequently altered genes. Among patients with BRAFV600 mutated melanoma, 44.5% (77 of 173) harbored at least one concurrent alteration driving potential resistance to mitogen-activated protein kinase inhibitors. In patients with RAS hotspot mutated lesions and in patients with neither BRAFV600 nor RAS hotspot mutations, alterations constituting potential pharmacological targets were found in 56.9% (66 of 116) and 47.7% (63 of 132) of cases, respectively.
CONCLUSIONS
Our tailored next-generation sequencing assay coupled with a comprehensive analysis may improve therapeutic management in a significant number of patients with melanoma. Updating such a panel and implementing multi-omic approaches will further enhance patients' clinical management.
Identifiants
pubmed: 33151472
doi: 10.1007/s11523-020-00764-4
pii: 10.1007/s11523-020-00764-4
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
759-771Références
Ali Z, Yousaf N, Larkin J. Melanoma epidemiology, biology and prognosis. EJC Suppl. 2013;11:81–91.
pubmed: 26217116
pmcid: 4041476
Reddy BY, Miller DM, Tsao H. Somatic driver mutations in melanoma. Cancer. 2017;123:2104–17.
pubmed: 28543693
Hodis E, Watson IR, Kryukov GV, Arold ST, Imielinski M, Theurillat J-P, et al. A landscape of driver mutations in melanoma. Cell. 2012;150:251–63.
pubmed: 22817889
pmcid: 3600117
Robert C, Karaszewska B, Schachter J, Rutkowski P, Mackiewicz A, Stroiakovski D, et al. Improved overall survival in melanoma with combined dabrafenib and trametinib. N Engl J Med. 2015;372:30–9.
pubmed: 25399551
Ascierto PA, McArthur GA, Dréno B, Atkinson V, Liszkay G, Di Giacomo AM, et al. Cobimetinib combined with vemurafenib in advanced BRAF(V600)-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial. Lancet Oncol. 2016;17:1248–60.
pubmed: 27480103
Larkin J, Hodi FS, Wolchok JD. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med. 2015;373:1270–1.
pubmed: 26398076
Wolchok JD, Chiarion-Sileni V, Gonzalez R, Rutkowski P, Grob J-J, Cowey CL, et al. Overall survival with combined nivolumab and ipilimumab in advanced melanoma. N Engl J Med. 2017;377:1345–56.
pubmed: 28889792
pmcid: 5706778
Fisher KE, Zhang L, Wang J, Smith GH, Newman S, Schneider TM, et al. Clinical validation and implementation of a targeted next-generation sequencing assay to detect somatic variants in non-small cell lung, melanoma, and gastrointestinal malignancies. J Mol Diagn. 2016;18:299–315.
pubmed: 26801070
pmcid: 4816706
Siroy AE, Boland GM, Milton DR, Roszik J, Frankian S, Malke J, et al. Beyond BRAF(V600): clinical mutation panel testing by next-generation sequencing in advanced melanoma. J Investig Dermatol. 2015;135:508–15.
pubmed: 25148578
Miraflor AP, de Abreu FB, Peterson JD, Turner SA, Amos CI, Tsongalis GJ, et al. Somatic mutation analysis in melanoma using targeted next generation sequencing. Exp Mol Pathol. 2017;103:172–7.
pubmed: 28822769
de Unamuno BB, Murria Estal R, Pérez Simó G, de Juan JI, Escutia Muñoz B, Rodríguez Serna M, et al. Towards personalized medicine in melanoma: implementation of a clinical next-generation sequencing panel. Sci Rep. 2017;7:495.
Sharma P, Hu-Lieskovan S, Wargo JA, Ribas A. Primary, adaptive, and acquired resistance to cancer immunotherapy. Cell. 2017;168:707–23.
pubmed: 28187290
pmcid: 5391692
Van Allen EM, Wagle N, Sucker A, Treacy DJ, Johannessen CM, Goetz EM, et al. The genetic landscape of clinical resistance to RAF inhibition in metastatic melanoma. Cancer Discov. 2014;4:94–109.
pubmed: 24265153
Wagle N, Van Allen EM, Treacy DJ, Frederick DT, Cooper ZA, Taylor-Weiner A, et al. MAP kinase pathway alterations in BRAF-mutant melanoma patients with acquired resistance to combined RAF/MEK inhibition. Cancer Discov. 2014;4:61–8.
pubmed: 24265154
Mourah S, How-Kit A, Meignin V, Gossot D, Lorillon G, Bugnet E, et al. Recurrent NRAS mutations in pulmonary Langerhans cell histiocytosis. Eur Respir J. 2016;47:1785–96.
pubmed: 27076591
Diefenbach RJ, Lee JH, Menzies AM, Carlino MS, Long GV, Saw RPM, et al. Design and testing of a custom melanoma next generation sequencing panel for analysis of circulating tumor DNA. Cancers (Basel). 2020;12:2228.
pmcid: 7465941
Louveau B, Jouenne F, Reger de Moura C, Sadoux A, Baroudjian B, Delyon J, et al. Baseline genomic features in BRAFV600-mutated metastatic melanoma patients treated with BRAF inhibitor + MEK inhibitor in routine care. Cancers. 2019;11:1203.
pmcid: 6721518
Cancer Genome Atlas Network. Genomic classification of cutaneous melanoma. Cell. 2015;161:1681–96.
Marconcini R, Galli L, Antonuzzo A, Bursi S, Roncella C, Fontanini G, et al. Metastatic BRAF K601E-mutated melanoma reaches complete response to MEK inhibitor trametinib administered for over 36 months. Exp Hematol Oncol. 2017;6:6.
pubmed: 28344857
pmcid: 5361706
Bowyer SE, Rao AD, Lyle M, Sandhu S, Long GV, McArthur GA, et al. Activity of trametinib in K601E and L597Q BRAF mutation-positive metastatic melanoma. Melanoma Res. 2014;24:504–8.
pubmed: 24933606
Del Regno L, Louveau B, Battistella M, Sadoux A, Baroudjian B, Delyon J, et al. Clinical significance of BRAF/NRAS concurrent mutations in a clinic-based metastatic melanoma cohort. Br J Dermatol. 2020;182(5):1281–3.
pubmed: 31675434
Emery CM, Vijayendran KG, Zipser MC, Sawyer AM, Niu L, Kim JJ, et al. MEK1 mutations confer resistance to MEK and B-RAF inhibition. Proc Natl Acad Sci USA. 2009;106:20411–6.
pubmed: 19915144
pmcid: 2777185
Kinoshita-Kikuta E, Kinoshita E, Ueda S, Ino Y, Kimura Y, Hirano H, et al. Increase in constitutively active MEK1 species by introduction of MEK1 mutations identified in cancers. Biochim Biophys Acta Proteins Proteom. 2019;1867:62–70.
pubmed: 29753091
Manca A, Lissia A, Capone M, Ascierto PA, Botti G, Caracò C, et al. Activating PIK3CA mutations coexist with BRAF or NRAS mutations in a limited fraction of melanomas. J Transl Med. 2015;13:37.
pubmed: 25627962
pmcid: 4312444
Watson IR, Li L, Cabeceiras PK, Mahdavi M, Gutschner T, Genovese G, et al. The RAC1 P29S hotspot mutation in melanoma confers resistance to pharmacological inhibition of RAF. Cancer Res. 2014;74:4845–52.
pubmed: 25056119
pmcid: 4167745
Shi H, Hugo W, Kong X, Hong A, Koya RC, Moriceau G, et al. Acquired resistance and clonal evolution in melanoma during BRAF inhibitor therapy. Cancer Discov. 2014;4:80–93.
pubmed: 24265155
Smalley KSM, Lioni M, Palma MD, Xiao M, Desai B, Egyhazi S, et al. Increased cyclin D1 expression can mediate BRAF inhibitor resistance in BRAF V600E-mutated melanomas. Mol Cancer Ther. 2008;7:2876.
pubmed: 18790768
pmcid: 2651569
Yadav V, Burke TF, Huber L, Van Horn RD, Zhang Y, Buchanan SG, et al. The CDK4/6 inhibitor LY2835219 overcomes vemurafenib resistance resulting from MAPK reactivation and cyclin D1 upregulation. Mol Cancer Ther. 2014;13:2253–63.
pubmed: 25122067
Flaherty K, Davies MA, Grob JJ, Long GV, Nathan P, Ribas A, et al. Genomic analysis and 3-year efficacy and safety update of COMBI-d. J Clin Oncol. 2016;34(15_Suppl.):9502.
Sheppard KE, AbuHammad S. CDK4/6 inhibition in cancer: the cell cycle splicing connection. Mol Cell Oncol. 2019;6:e1673643.
pubmed: 31692881
pmcid: 6816418
Riaz N, Havel JJ, Kendall SM, Makarov V, Walsh LA, Desrichard A, et al. Recurrent SERPINB3 and SERPINB4 mutations in patients who respond to anti-CTLA4 immunotherapy. Nat Genet. 2016;48:1327–9.
pubmed: 27668655
pmcid: 5553281
Dankort D, Curley DP, Cartlidge RA, Nelson B, Karnezis AN, Damsky WE, et al. Braf(V600E) cooperates with Pten loss to induce metastatic melanoma. Nat Genet. 2009;41:544–52.
pubmed: 19282848
pmcid: 2705918
Irvine M, Stewart A, Pedersen B, Boyd S, Kefford R, Rizos H. Oncogenic PI3K/AKT promotes the step-wise evolution of combination BRAF/MEK inhibitor resistance in melanoma. Oncogenesis. 2018;7:72.
pubmed: 30237495
pmcid: 6148266
Gold HL, Wengrod J, de Miera EV-S, Wang D, Fleming N, Sikkema L, et al. PP6C hotspot mutations in melanoma display sensitivity to Aurora kinase inhibition. Mol Cancer Res. 2014;12:433–9.
pubmed: 24336958
Mondesir J, Willekens C, Touat M, de Botton S. IDH1 and IDH2 mutations as novel therapeutic targets: current perspectives. J Blood Med. 2016;7:171–80.
pubmed: 27621679
pmcid: 5015873
Yu H, Ma M, Yan J, Xu L, Yu J, Dai J, et al. Identification of coexistence of BRAF V600E mutation and EZH2 gain specifically in melanoma as a promising target for combination therapy. J Transl Med. 2017;15:243.
pubmed: 29202777
pmcid: 5716227
Wang W, Hu B, Qin J-J, Cheng J-W, Li X, Rajaei M, et al. A novel inhibitor of MDM2 oncogene blocks metastasis of hepatocellular carcinoma and overcomes chemoresistance. Genes Dis. 2019;6:419–30.
pubmed: 31832522
pmcid: 6889017
Wu C-E, Esfandiari A, Ho Y-H, Wang N, Mahdi AK, Aptullahoglu E, et al. Targeting negative regulation of p53 by MDM2 and WIP1 as a therapeutic strategy in cutaneous melanoma. Br J Cancer. 2018;118:495–508.
pubmed: 29235570
Dankner M, Rose AAN, Rajkumar S, Siegel PM, Watson IR. Classifying BRAF alterations in cancer: new rational therapeutic strategies for actionable mutations. Oncogene. 2018;37:3183–99.
pubmed: 29540830
Schettini F, De Santo I, Rea CG, De Placido P, Formisano L, Giuliano M, et al. CDK 4/6 inhibitors as single agent in advanced solid tumors. Front Oncol. 2018;8:608.
pubmed: 30631751
pmcid: 6315195
Patnaik A, Rosen LS, Tolaney SM, Tolcher AW, Goldman JW, Gandhi L, et al. Efficacy and safety of abemaciclib, an inhibitor of CDK4 and CDK6, for patients with breast cancer, non-small cell lung cancer, and other solid tumors. Cancer Discov. 2016;6:740–53.
pubmed: 27217383
Carvajal RD, Antonescu CR, Wolchok JD, Chapman PB, Roman R-A, Teitcher J, et al. KIT as a therapeutic target in metastatic melanoma. JAMA. 2011;305:2327–34.
pubmed: 21642685
pmcid: 3986039
Das I, Wilhelm M, Höiom V, Marquez RF, Svedman FC, Hansson J, et al. Combining ERBB family and MET inhibitors is an effective therapeutic strategy in cutaneous malignant melanoma independent of BRAF/NRAS mutation status. Cell Death Dis. 2019;10:1–16.
Lau C, Killian KJ, Samuels Y, Rudloff U. ERBB4 mutation analysis: emerging molecular target for melanoma treatment. Methods Mol Biol. 2014;1102:461–80.
pubmed: 24258993
pmcid: 5125540
Prickett TD, Agrawal NS, Wei X, Yates KE, Lin JC, Wunderlich J, et al. Analysis of the tyrosine kinome in melanoma reveals recurrent mutations in ERBB4. Nat Genet. 2009;41:1127–32.
pubmed: 19718025
pmcid: 2897709
Capparelli C, Rosenbaum S, Berman-Booty LD, Salhi A, Gaborit N, Zhan T, et al. ErbB3–ErbB2 complexes as a therapeutic target in a subset of wild-type BRAF/NRAS cutaneous melanomas. Cancer Res. 2015;75:3554–67.
pubmed: 26206558
pmcid: 4558382
Capparelli C, Purwin TJ, Heilman SA, Chervoneva I, McCue PA, Berger AC, et al. ErbB3 targeting enhances the effects of MEK inhibitor in wild-type BRAF/NRAS melanoma. Cancer Res. 2018;78:5680–93.
pubmed: 30115691
pmcid: 6168374
Arafeh R, Qutob N, Emmanuel R, Keren-Paz A, Madore J, Elkahloun A, et al. Recurrent inactivating RASA2 mutations in melanoma. Nat Genet. 2015;47:1408–10.
pubmed: 26502337
pmcid: 4954601
Tsao H, Chin L, Garraway LA, Fisher DE. Melanoma: from mutations to medicine. Genes Dev. 2012;26:1131–55.
pubmed: 22661227
pmcid: 3371404
Smalley I, Smalley KSM. ERK inhibition: a new front in the war against MAPK pathway-driven cancers? Cancer Discov. 2018;8:140–2.
pubmed: 29431672
Olbryt M, Pigłowski W, Rajczykowski M, Pfeifer A, Student S, Fiszer-Kierzkowska A. Genetic profiling of advanced melanoma: candidate mutations for predicting sensitivity and resistance to targeted therapy. Target Oncol. 2020;15:101–13.
pubmed: 31980996
pmcid: 7028806